

A Pilot Study to Assess How Safe and Effective Oral Roflumilast is for Treating Moderate to Severe Psoriasis in Adults

NCT07233291

| | |
|------------|-----------------|
| Status | RECRUITING |
| Phase | Phase 2 |
| Sponsor | Ahmed Ibrahim |
| Enrollment | 36 participants |

Key Eligibility Criteria

Inclusion (4)

- Psoriatic patients e 18 years in whom systemic therapy is indicated.
- Chronic stable plaque psoriasis.
- Patients who don't use other systemic therapy for psoriasis in the last 2 months (or naïve who didn't use any systemic therapy before).
- Safe contraception during the study.

Exclusion (9)

- Pregnant or lactating women, as well as women of childbearing potential not using an effective method of contraception.
- Age <18 years.
- Other concomitant psoriasis systemic treatments such as Acitretin and biologics.
- Previous systemic treatment of psoriasis in the last 2 months.
- Patients receiving inducers or inhibitors of cytochromes CYP3A4 and CYP1A.
- ... and 4 more (see full listing online)

Locations (1 total)

Mansoura University Hospital, Al Mansurah, Dakahlia Governorate, Egypt